{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:34:02Z","timestamp":1792953242941,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019871","name":"Castle Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01912-w","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:25:58Z","timestamp":1788841558000},"page":"5445-5458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Experience and Preferences for Treatments in Atopic Dermatitis"],"prefix":"10.1007","volume":"16","author":[{"given":"Diego Ruiz","family":"Dasilva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Burshtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani-Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka V.","family":"Hurton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Farberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"4","key":"1912_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417\u201328.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"1912_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"2","key":"1912_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.36849\/JDD.6408","volume":"21","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. The heterogeneity of atopic dermatitis. J Drugs Dermatol. 2022;21(2):172\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1912_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1912_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283\u20139.","journal-title":"Dermatol Clin"},{"issue":"3","key":"1912_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1912_CR7","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1912_CR8","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s12325-022-02197-z","volume":"39","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Lafeuille MH, Emond B, et al. Real-world effectiveness of newly initiated systemic therapy for atopic dermatitis in the United States: a claims database analysis. Adv Ther. 2022;39(9):4157\u201368.","journal-title":"Adv Ther"},{"issue":"1","key":"1912_CR9","first-page":"335","volume":"94","author":"CV D\u2019Angelo","year":"2026","unstructured":"D\u2019Angelo CV, Wilberger P, Merritt C, Burshtein J, Merritt D. Trends in dermatologic biologic prescribing: a medicare part D public use file analysis from 2018 to 2023. J Am Acad Dermatol. 2026;94(1):335\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1912_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.anai.2023.12.020","volume":"132","author":"A Samynathan","year":"2024","unstructured":"Samynathan A, Silverberg JI. Navigating the atopic dermatitis toolbox: challenging scenarios and shared decision-making. Ann Allergy Asthma Immunol. 2024;132(3):337\u201343.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1912_CR11","doi-asserted-by":"publisher","first-page":"adv41504","DOI":"10.2340\/actadv.v105.41504","volume":"105","author":"AR Schl\u00f6sser","year":"2025","unstructured":"Schl\u00f6sser AR, Nijman L, Schappin R, Nijsten TEC, Hijnen D. Long-term outcomes of new systemic agents in atopic dermatitis: drug survival analyses and treatment patterns in daily practice. Acta Derm Venereol. 2025;105:adv41504.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1912_CR12","first-page":"e102538","volume":"18","author":"T Sharma","year":"2026","unstructured":"Sharma T, Balasubramanian A, Dhoot D, Patil S, Barkate H. The atopic dermatitis patient journey: from awareness to advanced care. Cureus. 2026;18(1):e102538.","journal-title":"Cureus"},{"key":"1912_CR13","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3511","author":"F Ali","year":"2020","unstructured":"Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020. https:\/\/doi.org\/10.2340\/00015555-3511.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1912_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40257-017-0284-y","volume":"18","author":"W Wei","year":"2017","unstructured":"Wei W, Anderson P, Gadkari A, et al. Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey. Am J Clin Dermatol. 2017;18(6):825\u201335.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1912_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamadermatol.2023.2008","volume":"159","author":"V Long","year":"2023","unstructured":"Long V, Chen Z, Du R, et al. Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling. JAMA Dermatol. 2023;159(8):811.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1912_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1080\/09546634.2021.1961996","volume":"33","author":"CEE Choi","year":"2022","unstructured":"Choi CEE, Yee MYF, Tan LYL, Phan P. A qualitative study of dermatology patients and providers to understand discordant perceptions of symptom burden and disease severity. J Dermatolog Treat. 2022;33(4):2344\u201351.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1912_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bjd.20972","volume":"186","author":"BWM Arents","year":"2022","unstructured":"Arents BWM, van Zuuren EJ, Vermeulen S, Schoones JW, Fedorowicz Z. Global guidelines in dermatology mapping project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)? Br J Dermatol. 2022;186(5):792\u2013802.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1912_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40271-025-00794-y","volume":"19","author":"B Arents","year":"2026","unstructured":"Arents B, Capozza K, Dlova NC, Funk M, Koh MJA, Ogola R. The patient voice in atopic eczema guidelines: how do we make it standard practice? Patient (Auckl). 2026;19(2):163\u201371.","journal-title":"Patient (Auckl)"},{"issue":"3","key":"1912_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s13555-022-00683-4","volume":"12","author":"P Aggarwal","year":"2022","unstructured":"Aggarwal P, Bowers NL, Muddasani S, Fleischer AB, Feldman SR. Atopic dermatitis and psoriasis are diagnosed clinically and treated empirically. Dermatol Ther. 2022;12(3):611\u20134.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1912_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.36849\/JDD.7071","volume":"22","author":"P Lio","year":"2023","unstructured":"Lio P, Mauri D, Bates D, et al. Burden, control, and treatment of moderate to severe atopic dermatitis in 2021: a United States patient survey study. J Drugs Dermatol. 2023;22(2):119\u201331.","journal-title":"J Drugs Dermatol"},{"issue":"Supplement_2","key":"1912_CR21","doi-asserted-by":"publisher","first-page":"ljae266.081","DOI":"10.1093\/bjd\/ljae266.081","volume":"191","author":"AP Quick","year":"2024","unstructured":"Quick AP, Hurton LV, Zolochevska O, Farberg AS, Goldberg MS, Silverberg JI. 707 - contemporary systemic treatment patterns in atopic dermatitis. Br J Dermatol. 2024;191(Supplement_2):ljae266.081.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1912_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/09546634.2021.1898530","volume":"33","author":"NN Boytsov","year":"2022","unstructured":"Boytsov NN, Gorritz M, Wang X, Malatestinic WN, Wade RL, Goldblum OM. The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study. J Dermatolog Treat. 2022;33(3):1707\u201317.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1912_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2340\/00015555-3065","volume":"99","author":"K Kaaz","year":"2019","unstructured":"Kaaz K, Szepietowski JC, Matusiak \u0141. Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis. Acta Derm Venereol. 2019;99(2):175\u201380.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1912_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/derm.2022.29015.jsi","volume":"34","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Mohawk JA, Cirulli J, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. Dermatitis. 2023;34(2):135\u201344.","journal-title":"Dermatitis"},{"issue":"1","key":"1912_CR25","doi-asserted-by":"publisher","first-page":"2315145","DOI":"10.1080\/09546634.2024.2315145","volume":"35","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Chan AWM, Ammoury A, et al. Patients\u2019 and caregivers\u2019 perspectives of the atopic dermatitis journey. J Dermatolog Treat. 2024;35(1):2315145.","journal-title":"J Dermatolog Treat"},{"key":"1912_CR26","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/j.chbr.2022.100206","volume":"7","author":"MJ Wu","year":"2022","unstructured":"Wu MJ, Zhao K, Fils-Aime F. Response rates of online surveys in published research: a meta-analysis. Comput Hum Behav Rep. 2022;7:100206.","journal-title":"Comput Hum Behav Rep"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01912-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:00:50Z","timestamp":1792951250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01912-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01912-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lenka V. Hurton is an employee and stock\/options holder for Castle Biosciences, Inc. Joshua Burshtein received fellowship funds from Castle Biosciences, Inc. Aaron S. Farberg is a consultant for Castle Biosciences, Inc. and on the advisory board for Amgen, Boehringer Ingelheim, Eli Lilly, Galderma, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, and Sun Pharma; is an editorial board member of Dermatology and Therapy and was not involved in the selection of peer reviewers nor any subsequent editorial decisions. Peter A. Lio reports research grants\/funding from AbbVie, AOBiome, Eczema Foundation, National Eczema Association; is on the speaker's bureau for AbbVie, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay\/L\u2019Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron\/Sanofi Genzyme; reports consulting\/advisory boards for AbbVie, Almirall, Amyris, Arbonne, ASLAN, Bodewell, Boston Skin Science, Bristol-Myers Squibb, Burt\u2019s Bees, Castle Biosciences, Inc., Codex Labs, Concerto Biosci, Dermavant, Dermira, DermVeda, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosci, Kimberly Clark, LEO Pharma, Lipidor, L\u2019Oreal, Menlo Therapeutics, Merck, Micreos, MyOR Diagnostics, Regeneron\/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Theraplex, UCB, Unilever, Verrica, Yobee Care; stock options with LearnSkin\/Learn Health, Medable, Micreos, Modernizing Medicine, Yobee Care. In addition, Peter A. Lio has a patent pending for a Theraplex product with royalties paid and is a Board member and Scientific Advisory Committee Member of the National Eczema Association. Diego Ruiz Dasilva is a consultant\/speaker for AbbVie, Arcutis, Dermavant\/Organon, Galderma, Incyte, Johnson & Johnson, LEO, Pfizer, Regeneron, Sanofi, UCB, Takeda, Eli Lilly, Verica, Vanta Diagnostics & Castle Biosciences, Inc. John Koo is a speaker for Abbvie, Amgen, BMS, Eli Lilly, Gelderma, Leo, Pfizer, Regeneron, Sanofi, Sun, a consultant for Castle Biosciences, Inc., Janssen, Leo and Sun. AF is a consultant or advisor for Kenvue, Galderma Laboratories, L.P., Hoth Therapeutics, Incyte Corporation, Johnson & Johnson, La-Roche Posay, Lilly, L'Or\u00e9al S.A., MINO Labs, Novartis, Novocure, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Leo Pharma, Arcutis Abbvie; reports research funding from: Galderma Laboratories, L.P., Incyte Corporation, Janssen, MINO Labs, Pfizer, Inc.; is on speakers bureau for: Incyte Corporation, Johnson & Johnson, Lilly, Regeneron Pharmaceuticals, Inc., Sanofi, Novartis, Arcutis, Pfizer, and UCB Pharma, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participation in the survey was voluntary. Informed consent to participate was obtained from all participants prior to their inclusion in the study. Participants were provided a link to complete the survey that was not participant-specific. Risk to participants was considered minimal as no protected health information or identifying information was collected.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}